Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer

Journal of Urology

Volumn 186, Issue 3, 2011, Pages 877-881

  Hall, Simon J ^a   Klotz, Laurence ^b   Pantuck, Allan J ^c   George, Daniel J ^d   Whitmore, James B ^e   Frohlich, Mark W ^e   Sims, Robert B ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY   (United States)

^e Dendreon   (United States)

Author keywords

drug toxicity; immunotherapy; prostate; prostatic neoplasms; sipuleucel T

Indexed keywords

PROVENGE;

ACUTE KIDNEY FAILURE; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOLOGOUS CELLULAR IMMUNOTHERAPY; BACKACHE; CANCER IMMUNOTHERAPY; CATHETER INFECTION; CEREBROVASCULAR ACCIDENT; CHILL; CITRATE TOXICITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOXIA; INCIDENCE; INJECTION SITE REACTION; KERATOCONJUNCTIVITIS SICCA; LEUKAPHERESIS; LIMB PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NAUSEA; ORAL PARESTHESIA; PARESTHESIA; PERNICIOUS ANEMIA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; SIDE EFFECT; SPINAL CORD COMPRESSION; STAPHYLOCOCCAL BACTEREMIA; TRANSIENT ISCHEMIC ATTACK; ULCERATIVE COLITIS; URINE RETENTION; VOMITING;

AGED; CANCER VACCINES; DOUBLE-BLIND METHOD; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE EXTRACTS;

EID: 80051548463     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.04.070     Document Type: Article

References (19)

1. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147
2. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
3. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506
4. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458
5. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411
6. T.M. Beer, G.T. Bernstein, and J.M. Corman Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC) 2007 ASCO Annual Meeting Proceedings Part I J Clin Oncol 25 suppl 2007 abstract 5059
7. C.S. Higano, P.F. Schellhammer, and E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670
8. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089
9. E.J. Small, P. Fratesi, and D.M. Reese Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 2000 3894
10. T.R. Fleming Identifying and addressing safety signals in clinical trials N Engl J Med 359 2008 1400
11. Reviewer Guidance: Conducting a Clinical Safety Review on a New Product Application and Preparing a Report on the Review 2005 United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Information, Office of Training and Communication Rockville
12. Common Terminology Criteria for Adverse Events v3.0 http://ctep.cancer. gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf 2006 Accessed September 3, 2010
13. R.O. Dillman Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy Cancer Metastasis Rev 18 1999 465
14. J.M. Kirkwood, J.G. Ibrahim, and V.K. Sondak High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444
15. E. Maggi, A. Vultaggio, and A. Matucci Acute infusion reactions induced by monoclonal antibody therapy Expert Rev Clin Immunol 7 2011 55
16. N.A. Sheikh, and L.A. Jones CD54 is a surrogate marker of antigen presenting cell activation Cancer Immunol Immunother 57 2008 1381
17. B. Alberts, A. Johnson, and J. Lewis Molecular Biology of the Cell 4th ed. 2005 Garland Science London, United Kingdom
18. A. Ibrahim, and J. Johnson FDA Clinical Briefing Document for the Oncologic Drug Advisory Committee September 13, 2005 Meeting 2005 Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research Rockville
19. A.C. Cunha, B. Weigle, and A. Kiessling Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues Cancer Lett 236 2006 229